Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer and other complex diseases. The concept of Epigenomics’ diagnostic tests for disease classification depends on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients based on its proprietary technology, Digital Phenotype®.